{"id":"epoetin-alfa-once-weekly","safety":{"commonSideEffects":[{"rate":"20-30","effect":"Hypertension"},{"rate":"10-20","effect":"Headache"},{"rate":"10-15","effect":"Arthralgia"},{"rate":"10-15","effect":"Fatigue"},{"rate":"5-10","effect":"Thrombotic events (venous thromboembolism)"},{"rate":"<1","effect":"Pure red cell aplasia"}]},"_chembl":{"chemblId":"CHEMBL1201565","moleculeType":"Protein"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Epoetin alfa is a glycoprotein that mimics endogenous erythropoietin, a hormone produced by the kidneys that regulates red blood cell formation. By binding to erythropoietin receptors on erythroid progenitor cells in the bone marrow, it promotes their proliferation, differentiation, and maturation into mature red blood cells. The once-weekly formulation allows for less frequent dosing while maintaining therapeutic erythropoiesis.","oneSentence":"Epoetin alfa is a recombinant erythropoietin that stimulates red blood cell production by binding to erythropoietin receptors on bone marrow progenitor cells.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:11:16.567Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Anemia associated with chronic kidney disease"},{"name":"Anemia in patients with cancer receiving chemotherapy"},{"name":"Anemia in patients undergoing elective surgery"}]},"trialDetails":[{"nctId":"NCT00843882","phase":"PHASE3","title":"Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2009-01-29","conditions":"Anemia, Chronic Myelomonocytic Leukemia, De Novo Myelodysplastic Syndrome","enrollment":247},{"nctId":"NCT07422480","phase":"PHASE3","title":"A Study to Compare Elritercept With Epoetin Alfa to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions","status":"RECRUITING","sponsor":"Takeda","startDate":"2026-04-01","conditions":"Myelodysplastic Syndrome, Anemia","enrollment":300},{"nctId":"NCT07300111","phase":"PHASE3","title":"A Study to Evaluate Efficacy and Safety of QLG1218(Daprodustat) in Chinese Hemodialysis (HD)-Dependent Subjects With Anemia Associated With Chronic Kidney Disease (CKD)","status":"NOT_YET_RECRUITING","sponsor":"Qilu Pharmaceutical Co., Ltd.","startDate":"2025-12-31","conditions":"Anaemia","enrollment":100},{"nctId":"NCT03169881","phase":"PHASE3","title":"Darbepoetin Trial to Improve Red Cell Mass and Neuroprotection in Preterm Infants","status":"COMPLETED","sponsor":"NICHD Neonatal Research Network","startDate":"2017-09-20","conditions":"Neurocognitive, Neuroprotective, Neonatal","enrollment":650},{"nctId":"NCT07131280","phase":"NA","title":"National Collaborative Centre for Hepatic Regenerative Medicine (NC-CHRM): Single vs Repeated Cycle of Granulocyte Colony-Stimulating Factor (GCSF) & Darbepoetin in Early Decompensated Cirrhosis","status":"NOT_YET_RECRUITING","sponsor":"Institute of Liver and Biliary Sciences, India","startDate":"2025-09","conditions":"Decompensated Cirrhosis","enrollment":110},{"nctId":"NCT07002827","phase":"NA","title":"Effect of Single vs Repeated Cycles of a Combination of Granulocyte Colony Stimulating Factor and Darbepoetin vs Standard Medical Treatment on Immunometabolic Profile in Patient With Early Decompensated Cirrhosis.","status":"NOT_YET_RECRUITING","sponsor":"Institute of Liver and Biliary Sciences, India","startDate":"2025-05-30","conditions":"Decompensated Liver Cirrhosis","enrollment":60},{"nctId":"NCT04313153","phase":"PHASE3","title":"Trial Evaluating the Efficacy and Safety of Oral Vadadustat Once Daily (QD) and Three Times Weekly (TIW) for the Maintenance Treatment of Anemia in Hemodialysis Subjects Converting From Erythropoiesis-Stimulating Agents (ESAs)","status":"COMPLETED","sponsor":"Akebia Therapeutics","startDate":"2020-05-27","conditions":"Anemia","enrollment":319},{"nctId":"NCT02278341","phase":"PHASE3","title":"Roxadustat in the Treatment of Anemia in End Stage Renal Disease (ESRD) Patients on Stable Dialysis","status":"COMPLETED","sponsor":"Astellas Pharma Europe B.V.","startDate":"2014-11-21","conditions":"Anemia, End Stage Renal Disease (ESRD)","enrollment":838},{"nctId":"NCT05810311","phase":"PHASE2","title":"The Effect of Roxadustat on Renal Oxygenation in Diabetes Nephropathy","status":"NOT_YET_RECRUITING","sponsor":"Region Stockholm","startDate":"2025-06-01","conditions":"Diabetes Complications, Diabetes; Nephropathy (Manifestation)","enrollment":30},{"nctId":"NCT02021318","phase":"PHASE3","title":"Roxadustat in the Treatment of Anemia in Chronic Kidney Disease (CKD) Patients, Not on Dialysis, in Comparison to Darbepoetin Alfa","status":"COMPLETED","sponsor":"Astellas Pharma Europe B.V.","startDate":"2014-03-12","conditions":"Anemia in Chronic Kidney Disease in Non-dialysis Patients","enrollment":616},{"nctId":"NCT02952092","phase":"PHASE3","title":"A Study of Intermittent Oral Dosing of ASP1517 in Hemodialysis Chronic Kidney Disease Patients With Anemia","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2016-11-30","conditions":"Hemodialysis Chronic Kidney Disease Patients With Anemia","enrollment":303},{"nctId":"NCT01888445","phase":"PHASE2","title":"A Study to Investigate the Effect of ASP1517 After Intermittent Oral Dosing in Dialysis Chronic Kidney Disease Patients With Anemia Compared With Darbepoetin as a Reference Drug","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2013-03-28","conditions":"Renal Anemia Associated With Chronic Renal Failure (CRF)","enrollment":130},{"nctId":"NCT05265325","phase":"PHASE2","title":"A Study of AND017 to Treat Anemia in Chronic Kidney Disease Patients on Dialysis","status":"COMPLETED","sponsor":"Kind Pharmaceuticals LLC","startDate":"2023-05-03","conditions":"Renal Anemia","enrollment":175},{"nctId":"NCT05699109","phase":"","title":"Erythropoiesis Stimulating Agents for Anemia Management in Egyptian Hemodialysis Patients","status":"COMPLETED","sponsor":"Helwan University","startDate":"2021-01-01","conditions":"Anemia of Chronic Kidney Disease, Chronic Renal Failure, Chronic Renal Failure Anemia","enrollment":127},{"nctId":"NCT00436748","phase":"PHASE3","title":"Study to Assess Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Patients With Chronic Kidney Disease","status":"TERMINATED","sponsor":"Amgen","startDate":"2008-09-16","conditions":"Anemia, Chronic Kidney Disease, Kidney Disease","enrollment":116},{"nctId":"NCT03799627","phase":"PHASE2","title":"Study of Vadadustat in Hemodialysis Participants With Anemia Switching From Epoetin Alfa","status":"COMPLETED","sponsor":"Akebia Therapeutics","startDate":"2019-01-31","conditions":"Anemia, Dialysis-dependent Chronic Kidney Disease","enrollment":175},{"nctId":"NCT04484857","phase":"PHASE3","title":"Study of Roxadustat Conversion in Participants Receiving Stable ESA or as Initial Anemia Treatment in Hemodialysis Participants","status":"COMPLETED","sponsor":"Kyntra Bio","startDate":"2020-07-22","conditions":"Anemia Associated With End Stage Renal Disease","enrollment":283},{"nctId":"NCT01235923","phase":"PHASE2","title":"Randomized Study of Weekly Erythropoietin Dosing in Preterm Infants","status":"COMPLETED","sponsor":"University of New Mexico","startDate":"2006-04","conditions":"Preterm Infants","enrollment":20},{"nctId":"NCT03552393","phase":"PHASE2","title":"Ascertain the Optimal Starting Dose of Mircera Given Subcutaneously for Maintenance Treatment of Anemia in Pediatric Patients With Chronic Kidney Disease on Dialysis or Not Yet on Dialysis.","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2018-08-03","conditions":"Anemia, Renal Insufficiency, Chronic","enrollment":40},{"nctId":"NCT00717821","phase":"PHASE3","title":"A Study of Once Monthly Intravenous or Subcutaneous Mircera in Participants With Chronic Kidney Disease on Hemodialysis.","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2008-08","conditions":"Anemia","enrollment":421},{"nctId":"NCT00514813","phase":"PHASE4","title":"Dynepo Long-Term Safety Study","status":"TERMINATED","sponsor":"Shire","startDate":"2007-06-06","conditions":"Anemia, Kidney Failure, Chronic","enrollment":152},{"nctId":"NCT04959578","phase":"PHASE4","title":"Comparison of Darbepoetin Alpha and Recombinant Human Erythropoietin for Treatment of Anemia in Children With Chronic Kidney Disease","status":"COMPLETED","sponsor":"Rufaida Mazahir","startDate":"2018-02-01","conditions":"Anemia of Chronic Kidney Disease","enrollment":50},{"nctId":"NCT04027517","phase":"PHASE3","title":"A Study to Evaluate Efficacy and Safety of JTZ-951 Compared to Darbepoetin Alfa in Korean Renal Anemia Patients Receiving Hemodialysis.","status":"COMPLETED","sponsor":"JW Pharmaceutical","startDate":"2019-01-15","conditions":"Anemia of Chronic Kidney Disease","enrollment":172},{"nctId":"NCT01023035","phase":"PHASE3","title":"Boceprevir/Peginterferon/Ribavirin for Chronic Hepatitis C: Erythropoietin Use Versus Ribavirin Dose Reduction for Anemia (P06086 AM2)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2009-12-07","conditions":"Hepatitis C, Chronic","enrollment":687},{"nctId":"NCT03543657","phase":"PHASE3","title":"Maintenance Treatment of Renal Anemia in Dialysis Subjects","status":"COMPLETED","sponsor":"Bayer","startDate":"2018-06-23","conditions":"Anemia, Renal Insufficiency, Chronic","enrollment":229},{"nctId":"NCT02969655","phase":"PHASE3","title":"A Study to Evaluate Efficacy and Safety of Daprodustat Compared to Darbepoetin Alfa in Japanese Hemodialysis (HD)-Dependent Subjects With Anemia Associated With Chronic Kidney Disease (CKD)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2016-11-21","conditions":"Anaemia","enrollment":271},{"nctId":"NCT02522975","phase":"PHASE4","title":"Biosimilar Erythropoietin in Anaemia Treatment (Correction Phase Study)","status":"TERMINATED","sponsor":"Shenyang Sunshine Pharmaceutical Co., LTD.","startDate":"2015-08","conditions":"Renal Anaemia","enrollment":16},{"nctId":"NCT00014222","phase":"PHASE3","title":"Combination Chemotherapy With or Without Colony-stimulating Factors in Treating Women With Breast Cancer","status":"COMPLETED","sponsor":"NCIC Clinical Trials Group","startDate":"2000-12-04","conditions":"Breast Cancer","enrollment":2104},{"nctId":"NCT00070382","phase":"PHASE3","title":"Darbepoetin Alfa Compared With Epoetin Alfa in Treating Anemia in Patients Receiving Chemotherapy for Cancer","status":"COMPLETED","sponsor":"Jonsson Comprehensive Cancer Center","startDate":"2003-08","conditions":"Anemia, Leukemia, Lymphoma","enrollment":14},{"nctId":"NCT03693950","phase":"PHASE1","title":"The Study of PK, PD, Safety of Multiple Intravenous Injections of BCD-066 and Aranesp in Healthy Volunteers","status":"COMPLETED","sponsor":"Biocad","startDate":"2017-03-28","conditions":"Healthy","enrollment":57},{"nctId":"NCT03104426","phase":"PHASE2, PHASE3","title":"EPO-4-Rhesus Study","status":"UNKNOWN","sponsor":"Sanquin-LUMC J.J van Rood Center for Clinical Transfusion Research","startDate":"2017-10-31","conditions":"Erythroblastosis, Fetal, Erythroblastosis Fetalis, Rh Disease, Erythroblastosis Fetalis Due to RH Antibodies","enrollment":42},{"nctId":"NCT01975818","phase":"PHASE2","title":"Maintenance Treatment of Anemia Associated With Chronic Kidney Disease (CKD) in Hemodialysis Subjects on Epoetin Alfa / Beta Treatment Versus BAY85-3934","status":"COMPLETED","sponsor":"Bayer","startDate":"2013-10-28","conditions":"Anemia, Renal Insufficiency, Chronic","enrollment":201},{"nctId":"NCT00334737","phase":"PHASE2","title":"Darbepoetin Administration to Preterm Infants","status":"COMPLETED","sponsor":"University of New Mexico","startDate":"2006-06","conditions":"Infant, Newborn","enrollment":102},{"nctId":"NCT02148367","phase":"PHASE2","title":"Effect of Recombinant Erythropoietin on Numbers of Circulating Endothelial Progenitor Cells in Subacute TBI","status":"WITHDRAWN","sponsor":"Uniformed Services University of the Health Sciences","startDate":"2014-09","conditions":"Traumatic Brain Injury","enrollment":""},{"nctId":"NCT03776032","phase":"PHASE3","title":"A Novel Erythropoiesis Stimulating Protein (NESP; Darbopoetin Alfa) for the Treatment of Anemia in Lung Cancer Patients Receiving Multi-cycle Platinum-Containing Chemotherapy","status":"COMPLETED","sponsor":"Amgen","startDate":"1999-09-14","conditions":"Anemia","enrollment":320},{"nctId":"NCT00052221","phase":"NA","title":"Epoetin Alfa in Treating Fatigue in Patients With Advanced Solid Tumors Who Are Not Receiving Chemotherapy","status":"WITHDRAWN","sponsor":"M.D. Anderson Cancer Center","startDate":"2003-05-20","conditions":"Fatigue, Unspecified Adult Solid Tumor, Protocol Specific","enrollment":""},{"nctId":"NCT02761642","phase":"PHASE2","title":"A Study to Evaluate Efficacy and Safety of Epoetin Beta (NeoRecormon®) in Anemic Participants With Breast Cancer Undergoing Chemotherapy","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2004-02-29","conditions":"Anemia","enrollment":200},{"nctId":"NCT01695759","phase":"PHASE3","title":"Clinical Efficacy of Two Erythropoietin Drug in Participants With Secondary Anemia to Chronic Kidney Disease.","status":"TERMINATED","sponsor":"Azidus Brasil","startDate":"2013-12","conditions":"Chronic Kidney Disease, Anemia","enrollment":92},{"nctId":"NCT00338286","phase":"PHASE3","title":"A Study of Epoetin Alfa Plus Standard Supportive Care Versus Standard Supportive Care Only in Anemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2006-03-02","conditions":"Breast Cancer, Neoplasm Metastasis","enrollment":2098},{"nctId":"NCT00400686","phase":"NA","title":"Epoetin Alfa in Treating Anemia in Patients Undergoing Chemotherapy for Multiple Myeloma","status":"COMPLETED","sponsor":"The Cleveland Clinic","startDate":"2003-09","conditions":"Anemia, Multiple Myeloma, Plasma Cell Neoplasm","enrollment":31},{"nctId":"NCT00048048","phase":"PHASE2","title":"A Study of Mircera in Anemic Patients With Chronic Kidney Disease Not Yet on Dialysis.","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2002-03","conditions":"Anemia","enrollment":65},{"nctId":"NCT00661505","phase":"PHASE3","title":"A Study of Intravenous Mircera in Hemodialysis Patients With Chronic Renal Anemia","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2008-05-14","conditions":"Anemia","enrollment":132},{"nctId":"NCT02049346","phase":"PHASE4","title":"Comparison Among Erythropoietin Stimulating Agents","status":"COMPLETED","sponsor":"Hamad Medical Corporation","startDate":"2012-03","conditions":"Anemia of End Stage Renal Disease","enrollment":327},{"nctId":"NCT00717366","phase":"PHASE2","title":"Study to Determine Optimum Intravenous Starting Dose of MIRCERA for Treatment of Pediatric Participants With Anemia and Chronic Kidney Disease on Hemodialysis","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2008-07","conditions":"Renal Anemia","enrollment":64},{"nctId":"NCT00711958","phase":"PHASE3","title":"Study to Assess the Efficacy and Safety of HX575 in the Treatment of Chemotherapy Associated Anemia in Cancer Patients","status":"COMPLETED","sponsor":"Sandoz","startDate":"2004-11","conditions":"Anemia","enrollment":114},{"nctId":"NCT00017004","phase":"PHASE3","title":"Radiation Therapy and Cisplatin With or Without Epoetin Alfa in Treating Patients With Cervical Cancer and Anemia","status":"COMPLETED","sponsor":"Gynecologic Oncology Group","startDate":"2001-08","conditions":"Anemia, Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma","enrollment":114},{"nctId":"NCT00776425","phase":"PHASE4","title":"A Study of the Quality of Life and Treatment Response to Once Weekly Epoetin Beta (Recormon) Treatment in Anemic Participants With Solid and Lymphoid Malignancies","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2007-01","conditions":"Anemia","enrollment":117},{"nctId":"NCT01693029","phase":"PHASE3","title":"Study to Compare Safety and Efficacy of HX575 Epoetin Alfa and US-licensed Epoetin Alfa","status":"COMPLETED","sponsor":"Sandoz","startDate":"2012-09","conditions":"Anemia, Chronic Kidney Disease (CKD)","enrollment":435},{"nctId":"NCT00258440","phase":"NA","title":"Epoetin Alfa in Treating Patients With Anemia Who Are Undergoing Chemotherapy for Cancer","status":"TERMINATED","sponsor":"OHSU Knight Cancer Institute","startDate":"2003-05","conditions":"Anemia, Fatigue, Unspecified Adult Solid Tumor, Protocol Specific","enrollment":7},{"nctId":"NCT02210949","phase":"PHASE4","title":"Pre-operative Treatment With Erythropoietin and Iron Supplement in Cardiac Surgery","status":"TERMINATED","sponsor":"Catharina Ziekenhuis Eindhoven","startDate":"2014-08","conditions":"Heart; Dysfunction Postoperative, Cardiac Surgery, Anemia, Iron-Deficiency","enrollment":7},{"nctId":"NCT00286182","phase":"PHASE2","title":"Anemia in Heart Failure With a Preserved Ejection Fraction (HFPEF)","status":"COMPLETED","sponsor":"Mathew S. Maurer","startDate":"2007-07","conditions":"Anemia","enrollment":56},{"nctId":"NCT00394953","phase":"PHASE3","title":"A Study of Mircera for the Maintenance Treatment of Anemia in Dialysis Patients","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2006-12","conditions":"Anemia","enrollment":490},{"nctId":"NCT00077610","phase":"PHASE3","title":"A Study of Intravenous Mircera for the Treatment of Anemia in Dialysis Patients","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2004-02","conditions":"Anemia","enrollment":673},{"nctId":"NCT00364832","phase":"PHASE2","title":"A Study of Subcutaneous (sc) Mircera in Dialysis Patients With Chronic Renal Anemia.","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2001-10","conditions":"Anemia","enrollment":137},{"nctId":"NCT00048035","phase":"PHASE2","title":"A Study of Intravenous (iv) Mircera in Hemodialysis Patients With Chronic Renal Anemia","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2002-03","conditions":"Anemia","enrollment":91},{"nctId":"NCT02608060","phase":"PHASE4","title":"A Study to Assess the Hematopoyetic Response of Anemic Patients With Hematologic Malignancies Treated With Erythropoietin B","status":"TERMINATED","sponsor":"Hoffmann-La Roche","startDate":"2006-09","conditions":"Anemia","enrollment":4},{"nctId":"NCT02564094","phase":"PHASE4","title":"A Study of Epoetin Beta (NeoRecormon) in Participants With Solid Tumors or Hematologic Malignancies","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2005-02","conditions":"Anemia","enrollment":54},{"nctId":"NCT00081471","phase":"PHASE3","title":"A Study of Mircera in the Treatment of Anemia in Patients With Chronic Kidney Disease Not on Dialysis","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2004-06","conditions":"Anemia","enrollment":324},{"nctId":"NCT02624141","phase":"PHASE4","title":"A Study of Recormon (Epoetin Beta) in Anemic Patients With Non-Myeloid Malignancy","status":"TERMINATED","sponsor":"Hoffmann-La Roche","startDate":"2006-04","conditions":"Anemia","enrollment":10},{"nctId":"NCT00559273","phase":"PHASE3","title":"A Study of Subcutaneous Mircera Once Monthly in the Treatment of Anemia in Participants With Chronic Kidney Disease Not on Dialysis","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2007-12","conditions":"Renal Anemia, Chronic","enrollment":307},{"nctId":"NCT00605345","phase":"PHASE3","title":"A Study Comparing Subcutaneous Mircera and Darbepoetin Alfa for Maintenance Treatment of Anemia in Kidney Transplant Recipients.","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2007-12","conditions":"Anemia","enrollment":71},{"nctId":"NCT00446602","phase":"PHASE2","title":"A Phase 2 Study to Evaluate the Safety and Effectiveness of Once Weekly or Once Every Two Week Dosing of Epoetin Alfa in Anemic Patients With Low- or Intermediate-1 Risk Myelodysplastic Syndromes (MDS)","status":"WITHDRAWN","sponsor":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","startDate":"","conditions":"Myelodysplastic Syndromes, Anemia","enrollment":""},{"nctId":"NCT01478971","phase":"PHASE3","title":"Conversion Study From Epoetin Alfa to Monthly Peginesatide Injection in Patients With Chronic Kidney Disease on Dialysis","status":"COMPLETED","sponsor":"Takeda","startDate":"2011-10","conditions":"Chronic Kidney Disease, Anemia","enrollment":184},{"nctId":"NCT00058331","phase":"PHASE3","title":"Epoetin Alfa in Treating Anemia in Patients With Solid Tumors","status":"COMPLETED","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2003-06","conditions":"Anemia, Leukemia, Lymphoma","enrollment":365},{"nctId":"NCT00003600","phase":"PHASE3","title":"Epoetin Alfa in Treating Anemia in Patients Who Are Receiving Chemotherapy","status":"COMPLETED","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"1998-12","conditions":"Anemia, Breast Cancer, Chronic Myeloproliferative Disorders","enrollment":344},{"nctId":"NCT00321919","phase":"PHASE3","title":"A Study of Treatment With NeoRecormon (Epoetin Beta) in Patients With Chronic Renal Anemia","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2000-07","conditions":"Anemia","enrollment":605},{"nctId":"NCT01695746","phase":"","title":"An Observational Study of Mircera (Methoxy Polyethylene Glycol-Epoetin Beta) in Stage III-IV Chronic Kidney Disease Patients Not on Dialysis With Renal Anemia","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2011-08","conditions":"Anemia","enrollment":108},{"nctId":"NCT00077623","phase":"PHASE3","title":"A Study of Subcutaneous Mircera for the Treatment of Anemia in Dialysis Patients.","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2004-03","conditions":"Anemia","enrollment":572},{"nctId":"NCT00354341","phase":"PHASE3","title":"(ACORD Study) - A Study of NeoRecormon (Epoetin Beta) in Patients With Early Diabetic Nephropathy","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2002-09","conditions":"Anemia","enrollment":170},{"nctId":"NCT00924781","phase":"PHASE2","title":"A Study of the Efficacy and Safety of MK2578 for the Treatment of Anemia in Patients With Kidney Disease (MK2578-003-AM03-EXT12)","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2009-06","conditions":"Anemia, Chronic Kidney Disease","enrollment":39},{"nctId":"NCT02586402","phase":"PHASE2","title":"Safety & Efficacy of Pegolsihematide for Treatment of Anemia in Participants on Dialysis","status":"UNKNOWN","sponsor":"Jiangsu Hansoh Pharmaceutical Co., Ltd.","startDate":"2015-10","conditions":"Chronic Renal Failure, Anemia, Dialysis","enrollment":60},{"nctId":"NCT00869856","phase":"PHASE3","title":"Study to Evaluate the Efficacy, Safety and Immunogenicity of Subcutaneous HX575 in the Treatment of Anemia Associated With Chronic Kidney Disease (SWEEP)","status":"WITHDRAWN","sponsor":"Sandoz","startDate":"2009-04","conditions":"Anemia, Chronic Renal Insufficiency","enrollment":""},{"nctId":"NCT01111630","phase":"PHASE4","title":"Study of Erythropoietin (EPO) Administration Schedule","status":"COMPLETED","sponsor":"JW Pharmaceutical","startDate":"2009-10","conditions":"Chronic Renal Failure, Anaemia","enrollment":60},{"nctId":"NCT00440557","phase":"PHASE3","title":"An Efficacy and Safety Study of Epoetin Alfa for Initiation and Maintenance Treatment of Patients With Anemia Associated With Chronic Kidney Disease","status":"COMPLETED","sponsor":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","startDate":"2006-09","conditions":"Anemia","enrollment":375},{"nctId":"NCT00264108","phase":"","title":"Cost-effectiveness Study of Epoetin Alfa and Darbepoetin Alfa in Adult Patients With Cancer Who Have Anemia","status":"COMPLETED","sponsor":"Janssen-Cilag B.V.","startDate":"2005-06","conditions":"Anemia, Neoplasms","enrollment":492},{"nctId":"NCT00440466","phase":"PHASE3","title":"PROCRIT Extended Dosing For Maintenance of Hemoglobin in Pre-Dialysis CKD Patients","status":"COMPLETED","sponsor":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","startDate":"2007-07","conditions":"Anemia, Renal Diseases","enrollment":430},{"nctId":"NCT00072059","phase":"PHASE2","title":"Ro 50-3821 in Treating Anemia in Patients Receiving Antineoplastic Therapy for Stage IIIB or Stage IV Non-Small Cell Lung Cancer","status":"COMPLETED","sponsor":"Jonsson Comprehensive Cancer Center","startDate":"2003-07","conditions":"Anemia, Lung Cancer","enrollment":""},{"nctId":"NCT00148421","phase":"PHASE3","title":"Study for the Treatment of Anemia in Patients With Non-myeloid Malignancies Receiving Multicycle Chemotherapy.","status":"COMPLETED","sponsor":"Amgen","startDate":"","conditions":"Anemia","enrollment":""},{"nctId":"NCT00597584","phase":"PHASE3","title":"Safety & Efficacy of Peginesatide for Maintenance Treatment of Anemia in Participants With Chronic Kidney Disease on Hemodialysis","status":"COMPLETED","sponsor":"Affymax","startDate":"2007-10","conditions":"Chronic Renal Failure, Chronic Kidney Disease, Anemia","enrollment":823},{"nctId":"NCT00597753","phase":"PHASE3","title":"Safety & Efficacy of Peginesatide for Maintenance Treatment of Anemia in Participants With Chronic Kidney Disease on Hemodialysis","status":"COMPLETED","sponsor":"Affymax","startDate":"2007-09","conditions":"Chronic Renal Failure, Chronic Kidney Disease, Anemia","enrollment":803},{"nctId":"NCT00228449","phase":"PHASE2","title":"Peginesatide for Anemia in Chronic Hemodialysis Patients","status":"COMPLETED","sponsor":"Affymax","startDate":"2005-07","conditions":"Anemia, Chronic Kidney Disease, Chronic Renal Failure","enrollment":165},{"nctId":"NCT00398749","phase":"","title":"Survey on the Treatment of Anemia Using Recombinant Human Erythropoietin 2 (STAR-2)","status":"COMPLETED","sponsor":"Janssen-Cilag B.V.","startDate":"2005-10","conditions":"Anemia, Neoplasms","enrollment":1927},{"nctId":"NCT00695396","phase":"PHASE3","title":"A Study Evaluating Epoetin Alfa 40,000 IU (International Units) Every Week or 80,000 IU Every Week Compared to Placebo in Patients With Low or Intermediate-1 Risk Myelodysplastic Syndromes at Risk for Transfusion","status":"TERMINATED","sponsor":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","startDate":"2008-06","conditions":"Myelodysplastic Syndromes, Anemia","enrollment":25},{"nctId":"NCT01099202","phase":"NA","title":"Procrit Versus No Procrit in Acute Lymphocytic Leukemia, Lymphoblastic Lymphoma, or Burkitt's Undergoing Induction/Consolidation Chemotherapy","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2003-03","conditions":"Leukemia","enrollment":109},{"nctId":"NCT00752791","phase":"PHASE2","title":"Efficacy and Safety of Peginesatide Injection for the Maintenance Treatment of Anemia in Peritoneal Dialysis Participants Previously Treated With Epoetin.","status":"COMPLETED","sponsor":"Takeda","startDate":"2008-10","conditions":"Anemia","enrollment":59},{"nctId":"NCT01394991","phase":"PHASE4","title":"A Safety Study of Epoetin Alfa in Patients With Cancer Who Have Chemotherapy-Related Anemia","status":"COMPLETED","sponsor":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","startDate":"2006-01","conditions":"Anemia, Neoplasms","enrollment":504},{"nctId":"NCT00090753","phase":"PHASE3","title":"A Study of Intravenous or Subcutaneous Methoxy Polyethylene Glycol-Epoetin Beta (RO0503821, Mircera) in Chronic Kidney Disease Patients With Renal Anemia","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2004-10","conditions":"Anemia","enrollment":1228},{"nctId":"NCT00442702","phase":"PHASE3","title":"A Study of Subcutaneous Mircera in Patients With Chronic Kidney Disease, Not on Dialysis.","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2007-09","conditions":"Anemia","enrollment":228},{"nctId":"NCT00454246","phase":"PHASE3","title":"A Study of Mircera in Hemoglobin Control of Patients Transitioning to Dialysis.","status":"TERMINATED","sponsor":"Hoffmann-La Roche","startDate":"2007-04","conditions":"Anemia","enrollment":111},{"nctId":"NCT00528593","phase":"PHASE2","title":"Epoetin Alfa for HIV-Associated Neuropathy Trial","status":"WITHDRAWN","sponsor":"Washington University School of Medicine","startDate":"2007-11","conditions":"HIV Infections, Neuropathy","enrollment":""},{"nctId":"NCT00563446","phase":"NA","title":"Study of the Efficacy of Darbepoetin Alfa in the Treatment of Renal Anemia","status":"COMPLETED","sponsor":"Hospital Authority, Hong Kong","startDate":"2005-07","conditions":"Anemia, Kidney Failure, Chronic, Peritoneal Dialysis, Continuous Ambulatory","enrollment":16},{"nctId":"NCT00341055","phase":"PHASE3","title":"A Study to Evaluate the Hematologic Response Rate (the Rate at Which the Hemoglobin Level Rises) of PROCRIT (Epoetin Alfa) Given at a Dose of 80,000 Units Once Weekly to Cancer Patients With Anemia Who Are Receiving Chemotherapy.","status":"COMPLETED","sponsor":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","startDate":"2003-06","conditions":"Anemia, Cancer, Chemotherapy","enrollment":69},{"nctId":"NCT00246298","phase":"PHASE2","title":"A Study to Assess the Effectiveness of PROCRIT (Epoetin Alfa) Dosing Every 2 Weeks Versus Once a Week in Anemic HIV-infected Patients","status":"TERMINATED","sponsor":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","startDate":"2005-10","conditions":"Anemia, HIV","enrollment":31},{"nctId":"NCT00350090","phase":"PHASE3","title":"A Study to Assess the Response Rate of PROCRIT (Epoetin Alfa) Given at a Dose of 40,000 Units Once a Week to Cancer Patients With Anemia Who Are Not Receiving Chemotherapy.","status":"TERMINATED","sponsor":"Ortho Biotech Products, L.P.","startDate":"2002-09","conditions":"Anemia, Neoplasms","enrollment":98},{"nctId":"NCT00436995","phase":"PHASE3","title":"Extension From Weekly to Once Every Other Week Darbepoetin Alfa Administration in Subjects With Chronic Kidney Disease Receiving Dialysis","status":"COMPLETED","sponsor":"Amgen","startDate":"2006-04","conditions":"Chronic Kidney Disease","enrollment":114},{"nctId":"NCT00117104","phase":"PHASE4","title":"Evaluating Aranesp® in Subjects With End Stage Renal Disease onChronic Hemodialysis","status":"COMPLETED","sponsor":"Amgen","startDate":"","conditions":"End Stage Renal Disease","enrollment":""},{"nctId":"NCT00628043","phase":"PHASE3","title":"Clinical Study of Epoetin Beta to Chemotherapy-Induced Anemia (CIA) Patients","status":"COMPLETED","sponsor":"Chugai Pharmaceutical","startDate":"2008-05","conditions":"Anemia","enrollment":160},{"nctId":"NCT00568542","phase":"PHASE4","title":"Chronic, Low Dose Erythropoetin Beta in Ischemic Cardiomyopathy","status":"COMPLETED","sponsor":"Charite University, Berlin, Germany","startDate":"2006-05","conditions":"Ischemic Cardiomyopathy","enrollment":28},{"nctId":"NCT00121602","phase":"PHASE3","title":"Efficacy Study: Darbepoetin Alfa for the Treatment of Anemia in Patients With Chronic Kidney Disease","status":"COMPLETED","sponsor":"Amgen","startDate":"2005-03","conditions":"Anemia, Kidney Disease","enrollment":446},{"nctId":"NCT00119587","phase":"PHASE3","title":"Darbepoetin Alfa Treatment of Anemia in Hemodialysis Subjects","status":"COMPLETED","sponsor":"Amgen","startDate":"2002-08","conditions":"Anemia","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":118,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["PROCRIT"],"phase":"phase_3","status":"active","brandName":"Epoetin alfa once weekly","genericName":"Epoetin alfa once weekly","companyName":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","companyId":"johnson-johnson-pharmaceutical-research-development-l-l-c","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Epoetin alfa is a recombinant erythropoietin that stimulates red blood cell production by binding to erythropoietin receptors on bone marrow progenitor cells. Used for Anemia associated with chronic kidney disease, Anemia in patients with cancer receiving chemotherapy, Anemia in patients undergoing elective surgery.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}